Neumora Therapeutics (NMRA) Short Interest Ratio & Short Volume $10.85 +0.35 (+3.33%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Neumora Therapeutics Short Interest DataNeumora Therapeutics (NMRA) has a short interest of 10.46 million shares, representing 19.25% of the float (the number of shares available for trading by the public). This marks a 6.63% increase in short interest from the previous month. The short interest ratio (days to cover) is 9.2, indicating that it would take 9.2 days of the average trading volume of 750,041 shares to cover all short positions.Current Short Interest10,460,000 sharesPrevious Short Interest9,810,000 sharesChange Vs. Previous Month+6.63%Dollar Volume Sold Short$103.97 millionShort Interest Ratio9.2 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares161,561,000 sharesFloat Size54,330,000 sharesShort Percent of Float19.25%Today's Trading Volume1,902,698 sharesAverage Trading Volume750,041 sharesToday's Volume Vs. Average254% Short Selling Neumora Therapeutics? Sign up to receive the latest short interest report for Neumora Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNMRA Short Interest Over TimeNMRA Days to Cover Over TimeNMRA Percentage of Float Shorted Over Time Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. Neumora Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/202410,460,000 shares $103.97 million +6.6%19.3%9.2 $9.94 11/15/20249,810,000 shares $106.34 million +4.7%18.2%9.2 $10.84 10/31/20249,370,000 shares $107.29 million +4.0%17.1%10 $11.45 10/15/20249,010,000 shares $144.88 million -6.9%16.4%10.5 $16.08 9/30/20249,680,000 shares $127.87 million +1.7%17.6%13.7 $13.21 9/15/20249,520,000 shares $114.53 million -4.6%17.3%10.7 $12.03 Get the Latest News and Ratings for NMRA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Neumora Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/20249,980,000 shares $114.77 million +4.0%18.2%12.7 $11.50 8/15/20249,600,000 shares $113.18 million +4.9%17.5%12 $11.79 7/31/20249,150,000 shares $117.67 million +3.3%16.7%11.2 $12.86 7/15/20248,860,000 shares $102.86 million +21.4%16.2%11.2 $11.61 6/30/20247,300,000 shares $71.76 million +13.7%13.4%9.3 $9.83 6/15/20246,420,000 shares $62.79 million -2.4%11.8%10.5 $9.78 5/31/20246,580,000 shares $65.14 million +4.3%12.0%9.9 $9.90 5/15/20246,310,000 shares $61.02 million -4.1%11.6%10.1 $9.67 4/30/20246,580,000 shares $59.81 million +12.1%12.3%11.2 $9.09 4/15/20245,870,000 shares $65.69 million +19.3%11.1%11.1 $11.19 3/31/20244,920,000 shares $67.65 million -2.2%10.1%10.8 $13.75 3/15/20245,030,000 shares $75.90 million +2.7%10.3%12.5 $15.09 2/29/20244,900,000 shares $86.39 million -2.0%10.1%17.1 $17.63 2/15/20245,000,000 shares $94.05 million +11.1%10.7%17.9 $18.81 1/31/20244,500,000 shares $67.05 million No Change9.3%16.7 $14.90 NMRA Short Interest - Frequently Asked Questions What is Neumora Therapeutics' current short interest? Short interest is the volume of Neumora Therapeutics shares that have been sold short but have not yet been closed out or covered. As of November 30th, traders have sold 10,460,000 shares of NMRA short. 19.25% of Neumora Therapeutics' shares are currently sold short. Learn More on Neumora Therapeutics' current short interest. What is a good short interest ratio for Neumora Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NMRA shares currently have a short interest ratio of 9.0. Learn More on Neumora Therapeutics's short interest ratio. Which institutional investors are shorting Neumora Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Neumora Therapeutics: Ikarian Capital LLC, and LMR Partners LLP. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Neumora Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 19.25% of Neumora Therapeutics' floating shares are currently sold short. Is Neumora Therapeutics' short interest increasing or decreasing? Neumora Therapeutics saw a increase in short interest in the month of November. As of November 30th, there was short interest totaling 10,460,000 shares, an increase of 6.6% from the previous total of 9,810,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Neumora Therapeutics' float size? Neumora Therapeutics currently has issued a total of 161,561,000 shares. Some of Neumora Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Neumora Therapeutics currently has a public float of 54,330,000 shares. How does Neumora Therapeutics' short interest compare to its competitors? 19.25% of Neumora Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Neumora Therapeutics: Halozyme Therapeutics, Inc. (6.81%), Krystal Biotech, Inc. (12.69%), Arcellx, Inc. (12.85%), ADMA Biologics, Inc. (5.46%), Immunovant, Inc. (20.39%), Scholar Rock Holding Co. (15.76%), CRISPR Therapeutics AG (21.26%), Denali Therapeutics Inc. (5.91%), Twist Bioscience Co. (16.26%), Vericel Co. (8.14%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Neumora Therapeutics stock? Short selling NMRA is an investing strategy that aims to generate trading profit from Neumora Therapeutics as its price is falling. NMRA shares are trading up $0.35 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Neumora Therapeutics? A short squeeze for Neumora Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NMRA, which in turn drives the price of the stock up even further. How often is Neumora Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NMRA, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies Halozyme Therapeutics Short Interest Data Krystal Biotech Short Interest Data Arcellx Short Interest Data ADMA Biologics Short Interest Data Immunovant Short Interest Data Scholar Rock Short Interest Data CRISPR Therapeutics Short Interest Data Denali Therapeutics Short Interest Data Twist Bioscience Short Interest Data Vericel Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NMRA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.